Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>Events>This Event
  Events - April 2014

7th Annual Proteins & Antibodies Congress

03 Apr 2014 - 04 Apr 2014 - London, UK

Bookmark and Share

Over 400 attendees working within Proteins, Antibodies and Biotherapeutics

Over 40 case studies, presentations and panel discussions

Co-Located with our Biosimilars & Biobetters Congress and Peptides Congress

4 interactive streams:

  • Antibody Discovery & Development
  • Protein Purification, Expression & Characterisation
  • Antibody Engineering
  • Biotherapeutics Optimisation

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

Oxford Global Conferences are proud to present the 7th Annual Proteins & Antibodies Congress, taking place on 3rd & 4th April 2014 at the Novotel London West, UK.

Over two days, this meeting will bring together over 400 senior-level decision makers working at the forefront of the proteins and antibodies field in Europe and the US. The conference programme consists of world-class keynote addresses, industry and academic led presentations and panel debates, creating an interactive platform for high-level scientific and business discussion.

Our panel of Antibody experts will discuss the latest antibody discovery targets and development platforms. Day Two will feature case studies on increasing clinical success rate and the latest insights into armed antibodies and antibody-cytokine fusions.

The Protein Purification, Expression & Characterisation stream will explore the critical issues in protein crystallisation, assays, protein folding and cell line selection.

The Biotherapeutics Optimisation stream will explore the areas of alternative scaffolds and targeted delivery. Our internationally renowned speakers will discuss overcoming the challenges of immunogenicity and aggregation and debate the future of biopharmaceutical development.

Further information
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos